CA2076023A1 - Utilisation de la 5-trans-prostaglandine f2a en tant qu'agent hypotenseur oculaire - Google Patents

Utilisation de la 5-trans-prostaglandine f2a en tant qu'agent hypotenseur oculaire

Info

Publication number: CA2076023A1
Authority: CA; Canada
Prior art keywords: trans; pgf2; ocular; alpha; prostaglandin
Prior art date: 1990-03-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002076023A

Other languages

English (en)

Inventor

David Frederick Woodward

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Allergan Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-03-19

Filing date

1991-02-12

Publication date

1991-09-20

1991-02-12 Application filed by Individual filed Critical Individual

1991-09-20 Publication of CA2076023A1 publication Critical patent/CA2076023A1/fr

Status Abandoned legal-status Critical Current

Links

DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 title description 4
239000002220 antihypertensive agent Substances 0.000 title description 3
239000000203 mixture Substances 0.000 claims abstract description 10
230000004410 intraocular pressure Effects 0.000 claims abstract description 8
238000000034 method Methods 0.000 claims abstract description 7
PXGPLTODNUVGFL-UAAPODJFSA-N 5-trans-PGF2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C\CCCC(O)=O PXGPLTODNUVGFL-UAAPODJFSA-N 0.000 claims abstract 7
150000003839 salts Chemical class 0.000 claims description 20
150000001875 compounds Chemical class 0.000 claims description 12
206010030043 Ocular hypertension Diseases 0.000 claims description 6
229940054534 ophthalmic solution Drugs 0.000 claims description 5
239000002997 ophthalmic solution Substances 0.000 claims description 5
230000000699 topical effect Effects 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims description 2
239000002552 dosage form Substances 0.000 claims description 2
239000000825 pharmaceutical preparation Substances 0.000 claims description 2
229940127557 pharmaceutical product Drugs 0.000 claims description 2
231100000252 nontoxic Toxicity 0.000 claims 3
230000003000 nontoxic effect Effects 0.000 claims 3
239000007788 liquid Substances 0.000 claims 2
239000003937 drug carrier Substances 0.000 abstract description 2
208000010412 Glaucoma Diseases 0.000 description 13
229960001342 dinoprost Drugs 0.000 description 13
PXGPLTODNUVGFL-YNNPMVKQSA-N prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 description 13
150000003180 prostaglandins Chemical class 0.000 description 13
229940094443 oxytocics prostaglandins Drugs 0.000 description 8
230000001077 hypotensive effect Effects 0.000 description 7
-1 l-isopropyl ester Chemical class 0.000 description 7
PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
230000000694 effects Effects 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
150000002500 ions Chemical class 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
208000001953 Hypotension Diseases 0.000 description 3
210000001742 aqueous humor Anatomy 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000036439 ocular surface hyperemia Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 2
201000002862 Angle-Closure Glaucoma Diseases 0.000 description 2
208000002177 Cataract Diseases 0.000 description 2
206010020565 Hyperaemia Diseases 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
206010030348 Open-Angle Glaucoma Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
125000002723 alicyclic group Chemical group 0.000 description 2
229960000711 alprostadil Drugs 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
230000003078 antioxidant effect Effects 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
229960002986 dinoprostone Drugs 0.000 description 2
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000009472 formulation Methods 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
208000021822 hypotensive Diseases 0.000 description 2
125000000896 monocarboxylic acid group Chemical group 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
230000035807 sensation Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
201000004569 Blindness Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
208000031969 Eye Hemorrhage Diseases 0.000 description 1
206010018307 Glaucoma and ocular hypertension Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
101100286668 Mus musculus Irak1bp1 gene Proteins 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
206010068960 Narrow anterior chamber angle Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000007950 Ocular Hypotension Diseases 0.000 description 1
208000022873 Ocular disease Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108010087367 P-glycoprotein 2 Proteins 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
244000292604 Salvia columbariae Species 0.000 description 1
235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
235000001498 Salvia hispanica Nutrition 0.000 description 1
101150094640 Siae gene Proteins 0.000 description 1
241000212342 Sium Species 0.000 description 1
HFCYZXMHUIHAQI-UHFFFAOYSA-N Thidiazuron Chemical compound C=1C=CC=CC=1NC(=O)NC1=CN=NS1 HFCYZXMHUIHAQI-UHFFFAOYSA-N 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
241000289690 Xenarthra Species 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
201000001326 acute closed-angle glaucoma Diseases 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
210000002159 anterior chamber Anatomy 0.000 description 1
229960001716 benzalkonium Drugs 0.000 description 1
CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
150000001767 cationic compounds Chemical class 0.000 description 1
201000005667 central retinal vein occlusion Diseases 0.000 description 1
235000014167 chia Nutrition 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
230000010339 dilation Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
150000002066 eicosanoids Chemical class 0.000 description 1
150000002169 ethanolamines Chemical class 0.000 description 1
210000000416 exudates and transudate Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
229960004716 idoxuridine Drugs 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
229910001411 inorganic cation Inorganic materials 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
230000007774 longterm Effects 0.000 description 1
208000018769 loss of vision Diseases 0.000 description 1
231100000864 loss of vision Toxicity 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000000463 material Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical class CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 1
210000001747 pupil Anatomy 0.000 description 1
230000001179 pupillary effect Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
208000004644 retinal vein occlusion Diseases 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
210000001585 trabecular meshwork Anatomy 0.000 description 1
230000008733 trauma Effects 0.000 description 1
230000004393 visual impairment Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CA002076023A 1990-03-19 1991-02-12 Utilisation de la 5-trans-prostaglandine f2a en tant qu'agent hypotenseur oculaire Abandoned CA2076023A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US49687990A	1990-03-19	1990-03-19
US496,879		1990-03-19

Publications (1)

Publication Number	Publication Date
CA2076023A1 true CA2076023A1 (fr)	1991-09-20

Family

ID=23974569

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002076023A Abandoned CA2076023A1 (fr)	1990-03-19	1991-02-12	Utilisation de la 5-trans-prostaglandine f2a en tant qu'agent hypotenseur oculaire

Country Status (7)

Country	Link
EP (1)	EP0521009A4 (fr)
JP (1)	JPH05505605A (fr)
CA (1)	CA2076023A1 (fr)
FI (1)	FI924205A7 (fr)
HU (1)	HUT61666A (fr)
IE (1)	IE910865A1 (fr)
WO (1)	WO1991014428A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5468778A (en) *	1992-09-24	1995-11-21	Allergan, Inc.	Method of lowering intraocular pressure by administering a pharmaceutical composition containing 7-(5-substituted cyclopentyl) and 7-(5-substituted-cyclopentenyl) 5-heptenoic acids and derivatives
DE69311361T2 (de) *	1992-10-13	1998-01-08	Alcon Lab Inc	Zusammensetzungen zur behandlung von glaukoma die prostaglandine und clonidinderivate enthalten
US6294563B1 (en)	1994-10-27	2001-09-25	Allergan Sales, Inc.	Combinations of prostaglandins and brimonidine or derivatives thereof
US6414021B1 (en) *	2000-08-25	2002-07-02	Sucampo Ag	Control of intraocular pressure during surgery
DE60315846T2 (de)	2002-10-04	2008-05-21	Tyco Healthcare Group Lp, Norwalk	Zusammenbau von chirurgischem klammerwerkzeug

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA715163B (en) *	1970-09-15	1972-04-26	Upjohn Co	Prostanoic acid derivatives
US4599353A (en) *	1982-05-03	1986-07-08	The Trustees Of Columbia University In The City Of New York	Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
SE8703854D0 (sv) *	1987-10-07	1987-10-07	Pharmacia Ab	Prostaglandinderivat for behandling av glaukom eller okuler hypertension

1991
- 1991-02-12 HU HU922572A patent/HUT61666A/hu unknown
- 1991-02-12 JP JP91505356A patent/JPH05505605A/ja active Pending
- 1991-02-12 FI FI924205A patent/FI924205A7/fi not_active Application Discontinuation
- 1991-02-12 WO PCT/US1991/000986 patent/WO1991014428A1/fr not_active Ceased
- 1991-02-12 EP EP19910905501 patent/EP0521009A4/en not_active Withdrawn
- 1991-02-12 CA CA002076023A patent/CA2076023A1/fr not_active Abandoned
- 1991-03-15 IE IE086591A patent/IE910865A1/en unknown

Also Published As

Publication number	Publication date
EP0521009A1 (fr)	1993-01-07
WO1991014428A1 (fr)	1991-10-03
JPH05505605A (ja)	1993-08-19
IE910865A1 (en)	1991-09-25
HUT61666A (en)	1993-03-01
FI924205L (fi)	1992-09-18
FI924205A0 (fi)	1992-09-18
HU9202572D0 (en)	1992-12-28
EP0521009A4 (en)	1993-02-24
FI924205A7 (fi)	1992-09-18

Legal Events

Date	Code	Title	Description
1998-02-12	FZDE	Discontinued

Publication	Publication Date	Title
CN100391461C (zh)	2008-06-04	降血压性脂质和噻吗洛尔组合物及其使用的方法
AU685591B2 (en)	1998-01-22	EP2-receptor agonists as agents for lowering intraocular pressure
US4599353A (en)	1986-07-08	Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
AU2002312221A1 (en)	2003-05-08	Hypotensive lipid (prostaglandin derivatives) and timolol compositions and methods of using same
US20110275711A1 (en)	2011-11-10	Method for treating macular edema
JP2000511530A (ja)	2000-09-05	高眼圧処置用の医薬としてのシクロペンタン（エン）酸，２―アルケニル誘導体
US20070049625A1 (en)	2007-03-01	EP2 receptor agonists for treating glaucoma
ES2358558T3 (es)	2011-05-11	Derivados de tiofeno como medicamentos para el tratamiento de la hipertensión ocular.
WO1991014428A1 (fr)	1991-10-03	UTILISATION DE 5-TRANS PROSTAGLANDINE F2α COMME AGENT HYPOTENSIF OCULAIRE
US5011856A (en)	1991-04-30	Use of prostaglandin F3 α as an ocular hypotensive agent
AU644422B2 (en)	1993-12-09	Use of 5-trans prostaglandin f2 alpha as an ocular hypotensive agent
AU644642B2 (en)	1993-12-16	Use of prostaglandin f3 alpha as an ocular hypotensive agent
US5194449A (en)	1993-03-16	Use of prostaglandin F3α as an ocular hypotensive agent
US6124353A (en)	2000-09-26	Method of treating ocular hypertension with 8-epi prostaglandins
AU2010202674B2 (en)	2013-12-19	Hypotensive lipid and timolol compositions and methods of using same
EP0396169A2 (fr)	1990-11-07	Composition pharmaceutique pour utilisation topique ophtalmique ayant une tolérance locale modifiée
JPH1171272A (ja)	1999-03-16	角膜新生血管増殖抑制剤
HK1174845A (en)	2013-06-21	Compositions and methods for lowering intraocular pressure
AU2014201651A1 (en)	2014-04-10	Hypotensive lipid and timolol compositions and methods of using same